(1S)-4-(3-苯氧基苯基)-1-膦酰基丁烷-1-磺酸 | 157126-18-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (1S)-4-(3-苯氧基苯基)-1-膦酰基丁烷-1-磺酸
• 英文名称: BMS 187745
• 英文别名: Benzenebutanesulfonic acid, 3-phenoxy-alpha-phosphono-, (alphaS)-；(1S)-4-(3-phenoxyphenyl)-1-phosphonobutane-1-sulfonic acid
• CAS: 157126-18-6
• 化学式: C₁₆H₁₉O₇PS
• 分子量: 386.362
• InChiKey: RCGCZPXSRLLKCK-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-(bromomethyl)-5-(p-methoxyphenyl)-1,3-dioxol-4-en-2-one 、 (1S)-4-(3-苯氧基苯基)-1-膦酰基丁烷-1-磺酸 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 生成 (1S)-1-[bis[[5-(4-methoxyphenyl)-2-oxo-1,3-dioxol-4-yl]methoxy]phosphoryl]-4-(3-phenoxyphenyl)butane-1-sulfonic acid
  参考文献：
  名称：

  A general synthesis of dioxolenone prodrug moieties

  摘要：

  A general method for the synthesis of dioxolenone prodrug moieties from appropriately substituted beta-ketoesters is described. This novel and versatile sequence allows for the synthesis of alkyl- or aryl-substituted dioxolenone alcohols 8 or bromides 9. Coupling of the bromides 9 to prepare bis-dioxolenone phosphonate prodrug esters is also presented. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)02386-3
• 作为产物：
  描述：

  [(S)-1-Dimethylthiocarbamoylsulfanyl-4-(3-phenoxy-phenyl)-butyl]-phosphonic acid 在 甲酸 、 双氧水 、 溶剂黄146 作用下， 生成 (1S)-4-(3-苯氧基苯基)-1-膦酰基丁烷-1-磺酸
  参考文献：
  名称：

  Enantioselective Synthesis of α-Phosphono Sulfonate Squalene Synthase Inhibitors:  Chiral Recognition in the Interactions of an α-Phosphono Sulfonate Inhibitor with Squalene Synthase

  摘要：

  DOI：

  10.1021/ja962505o

文献信息

• Methods of using .alpha.-phosphonosulfonate squalene synthetase
  申请人：Bristol-Myers Squibb Company

  公开号：US05470845A1

  公开（公告）日：1995-11-28

  .alpha.-Phosphonosulfonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula ##STR1## wherein R.sup.2 is OR.sup.5 or R.sup.5a ; R.sup.3 and R.sup.5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R.sup.5a is H, alkyl, arylalkyl or aryl; R.sup.4 is H, alkyl, aryl, arylalkyl, or cycloalkyl;, Z is H, halogen, lower alkyl or lower alkenyl; and R.sup.1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts and or prodrug esters of the phosphonic (phosphinic) and/or sulfonic acids.

  提供了抑制酶角鲨烯合酶并从而抑制胆固醇生物合成的.alpha.-磷酸磺酸酯化合物。这些化合物的化学式为##STR1##其中R.sup.2为OR.sup.5或R.sup.5a；R.sup.3和R.sup.5独立地为H、烷基、芳基烷基、芳基或环烷基；R.sup.5a为H、烷基、芳基烷基或芳基；R.sup.4为H、烷基、芳基、芳基烷基或环烷基；Z为H、卤素、低烷基或低烯基；R.sup.1为至少含有7个碳原子的疏水基团，为烷基、烯基、炔基、混合烯基-炔基、芳基、芳基烷基、环烷基、环烷基烷基、杂环芳基、杂环芳基烷基、环杂环烷基、环杂环烷基烷基；如上所述；包括磷酸(亚磷酸)和/或磺酸的药用可接受盐和/或前药酯。
• ANTI-BACTERIAL COMPOSITIONS AND METHODS INCLUDING TARGETING VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS
  申请人：Oldfield Eric

  公开号：US20120022024A1

  公开（公告）日：2012-01-26

  This disclosure relates to compositions and methods including for the inhibition, prevention, and/or treatment of microbial infections, including infections from such pathogens as Staphylococcus aureus.

  本公开涉及包括用于抑制、预防和/或治疗微生物感染的组合物和方法，包括对金黄色葡萄球菌等病原体引起的感染。
• Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors
  申请人：E.R. Squibb & Sons, Inc.

  公开号：EP0595635A1

  公开（公告）日：1994-05-04

  α-Phosphonosulfonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These comounds have the formula wherein R² is OR⁵ or R5a; R³ and R⁵ are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R5a is H, alkyl, arylalkyl or aryl; R4 is H, alkyl, aryl, arylalkyl, or cycloalkyl;, Z is H, halogen, lower alkyl or lower alkenyl; and R¹ is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts and or prodrug esters of the phosphonic (phosphinic) and/or sulfonic acids.

  提供了α-磷酸磺酸酯化合物，可抑制齿烷合酶酶并从而抑制胆固醇生物合成。这些化合物的化学式为：其中R²是OR⁵或R5a; R³和R⁵独立地为H，烷基，芳基烷基，芳基或环烷基; R5a为H，烷基，芳基烷基或芳基; R4为H，烷基，芳基，芳基烷基或环烷基; Z为H，卤素，低烷基或低烯基; R¹为至少含有7个碳的疏水基团，为烷基，烯基，炔基，混合烯基-炔基，芳基，芳基烷基，环烷基，环烷基烷基，杂环芳基，杂环芳基烷基，环杂芳基烷基，环杂芳基烷基烷基; 包括磷酸（磷酸酯）和/或磺酸的药物可接受盐和/或前药酯。
• ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS
  申请人：Nizet Victor

  公开号：US20090306021A1

  公开（公告）日：2009-12-10

  The disclosure provides compounds and methods to treat bacterial pathogenesis, and demonstrates that the S. aureus pigment is a virulence factor and potential novel target for antimicrobial therapy.
• ANTIMICROBIAL COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS
  申请人：NIZET Victor

  公开号：US20140154302A1

  公开（公告）日：2014-06-05

  The disclosure provides compounds and methods to treat a microbial or a bacterial pathogenesis, and demonstrates that the S. aureus pigment is a virulence factor and potential novel target for antimicrobial therapy.